Rx-360 Summary of the The European Commission's Recently Issued Two Final Guidances in Support of the EU Falsified Medicines Directive
The European Commission has recently issued two final guidances in support of the EU Falsified Medicines Directive.
The Guidelines on the Formalised Risk Assessment for Ascertaining the Appropriate Good Manufacturing Practice for Excipients of Medicinal Products for Human Use indicates that the appropriate GMP for excipients of medicinal products for human use are to be determined on the basis of a formalized risk assessment outlined in the guidelines.
The risk assessment is to take into account requirements under other appropriate quality systems as well as the source and intended use of the excipients and previous instances of quality defects. The MAH should have the risk assessment/management document for appropriate GMP for excipients available on site for review by GBMP inspectors. A risk assessment as set out in these guidelines should be carried out for excipients for authorized medicinal products for human use by 21 March 2016.
The Guidelines on Principles of Good Distribution Practice GDP of Active Substances for Medicinal Products for Human Use follow the same principles that underlie the guidelines of EudraLex Volume 4, Part II, Chapter 17, with regard to the distribution of active substances and the Guidelines of 5 November 2013 on Good Distribution Practice of medicinal products for human use. These guidelines provide stand-alone guidance of GDP for importers and distributors of active substances for medicinal products for human use. These guidelines do not apply to intermediates of active substances. Distributors of active substances for medicinal products for human use should follow these guidelines as of 21 September 2015.
To View or Download the Guidance on Risk Assessments for Excipients, Click Here
To View or Download the Guidance on GDP for APIs, Click Here
To View or Download the Rx-360 Summaries of the Guidances, Click Here
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance